Trial Profile
A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2021
Price :
$35
*
At a glance
- Drugs Acamprosate (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Synchroneuron
- 08 Apr 2021 Planned End Date changed from 1 Aug 2016 to 1 Feb 2016.
- 08 Apr 2021 Status changed from completed to withdrawn prior to enrolment.
- 14 Apr 2016 Status changed from recruiting to completed.